An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
SUMMARY Human epidermal growth factor receptor 2 (HER2) is upregulated in a subset of human breast cancers. However, the cancer cells often quickly develop an adaptive response to HER2 kinase inhibitors. We found that an epigenetic pathway involving MLL2 is crucial for growth of HER2+ cells and MLL2 reduces sensitivity of the cancer cells to a HER2 inhibitor, Lapatinib. Lapatinib-induced FOXO transcription factors, normally tumor-suppressing, paradoxically upregulate c-Myc epigenetically, in concert with a cascade of MLL2-associating epigenetic regulators, to dampen sensitivity of the cancer cells to Lapatinib. An epigenetic inhibitor suppressing c-Myc synergizes with Lapatinib to suppress cancer growth in vivo, partly by repressing the FOXO/c-Myc axis, unraveling an epigenetically regulated FOXO/c-Myc axis as a potential target to improve therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 2×
“Consistently, IBET synergized with lapatinib to suppress cell growth of BT474 cells, with a combination index (CI) of 0.61 (Fig- C ure 4A), where a CI 1 indicates a synergy (Chou, 2010).”
InfluentialSelective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 2×
“…a chromatin-associating protein that can bind acetylated histones via its BET domain to upregulate gene transcription (Dey et al., 2003), and recently developed BRD4 inhibitors suppress leukemia and sarcoma partly by suppressing c-Myc expression (Dawson et al., 2011; Filippakopoulos et al., 2010).”
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 2×
“…(human epidermal growth factor receptor 2/epidermal growth factor receptor) complex can activate a downstream cascade of protein kinases including phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT), promoting tumorigenesis by increasing cell proliferation and survival (Schlessinger, 2000).”
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 3×
“…Cancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc. the insulin-like growth factor-I receptor (IGF-IR) or a PTENmutation (Lu et al., 2001; Nagata et al., 2004), lapatinib exerts its antitumor activity in a PTEN-independent manner (Xia et al., 2007), and thus remains useful for treating…”
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · cited 11×
“Whereas the HER2/PI3K/AKT pathway is often upregulated or activated in multiple types of cancers (Courtney et al., 2010), targeted inhibition of this pathway has only met limited success due to reduced sensitivity via various mechanisms including upregulation of RTKs (Chandarlapaty et al., 2011; Garrett et al., 2011;…”
InfluentialMYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
Stressing the role of FoxO proteins in lifespan and disease
van der Horst, A., & Burgering, B. M. T. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2190 · Cited by 759
Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
Cited by
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Targeting oncogenic Myc as a strategy for cancer treatment
Chen, H., Liu, H., & Qing, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0008-7 · Cited by 806
FOXO transcription factors in cancer development and therapy
Coomans de Brachène, A., & Demoulin, J.-B. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2112-y · Cited by 284
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer
Chang, C. A., Jen, J., Jiang, S., Sayad, A., Mer, A. S., Brown, K. R., Nixon, A. M. L., Dhabaria, A., Tang, K. H., Venet, D., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1265 · Cited by 119
“Epigenetic mechanisms for lapatinib resistance involving the mixed lineage leukemia (MLL) complex and bromodomain extra terminal domain (BET) family members also have been proposed (19,20).”
BackgroundImproving the reliability of peer-reviewed publications: We are all in it together
Bustin, S. A., & Nolan, T. (2016) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2015.11.002 · Cited by 22
Metadata
- Authors
- Matkar, S., Sharma, P., Gao, S., Gurung, B., Katona, B. W., Liao, J., Muhammad, A. B., Kong, X.-C., Wang, L., Jin, G., Dang, C. V., & Hua, X.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 28
- Issue
- 4
- Pages
- 472-485
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2171990088
- Cited by
- 85
- References
- 9
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis. https://app.cochat.ai/papers/10.1016/j.ccell.2015.09.005
- The paper
- Matkar, S., Sharma, P., Gao, S., Gurung, B., Katona, B. W., Liao, J., Muhammad, A. B., Kong, X.-C., Wang, L., Jin, G., Dang, C. V., & Hua, X. (2015). An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis. Cancer Cell. https://doi.org/10.1016/j.ccell.2015.09.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.